C
7.25
-0.06 (-0.82%)
| Penutupan Terdahulu | 7.31 |
| Buka | 7.36 |
| Jumlah Dagangan | 456,567 |
| Purata Dagangan (3B) | 2,969,106 |
| Modal Pasaran | 571,220,608 |
| Harga / Pendapatan (P/E TTM) | 3.28 |
| Harga / Pendapatan (P/E Ke hadapan) | 4.68 |
| Harga / Jualan (P/S) | 5.94 |
| Harga / Buku (P/B) | 3.91 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Mar 2026 |
| Margin Keuntungan | 20.81% |
| Margin Operasi (TTM) | 51.49% |
| EPS Cair (TTM) | 0.250 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.41% |
| Nisbah Semasa (MRQ) | 4.21 |
| Aliran Tunai Operasi (OCF TTM) | -13.57 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -21.07 M |
| Pulangan Atas Aset (ROA TTM) | 8.31% |
| Pulangan Atas Ekuiti (ROE TTM) | 19.87% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | CorMedix Inc. | Menurun | Bercampur |
AISkor Stockmoo
1.5
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | 1.50 |
|
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company’s focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.08% |
| % Dimiliki oleh Institusi | 34.20% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Oberweis Asset Management Inc/ | 31 Dec 2025 | 805,115 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 15.00 (Needham, 106.90%) | Beli |
| Median | 13.50 (86.21%) | |
| Rendah | 13.00 (RBC Capital, 79.31%) | Beli |
| 13.00 (HC Wainwright & Co., 79.31%) | Beli | |
| Purata | 13.75 (89.66%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 7.39 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| D. Boral Capital | 11 Feb 2026 | 14.00 (93.10%) | Beli | 7.43 |
| 08 Jan 2026 | 14.00 (93.10%) | Beli | 7.51 | |
| HC Wainwright & Co. | 23 Jan 2026 | 13.00 (79.31%) | Beli | 7.27 |
| RBC Capital | 21 Jan 2026 | 13.00 (79.31%) | Beli | 7.33 |
| Needham | 08 Jan 2026 | 15.00 (106.90%) | Beli | 7.51 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 02 Feb 2026 | Pengumuman | CorMedix Therapeutics Announces Share Repurchase Program |
| 29 Jan 2026 | Pengumuman | CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026 |
| 09 Jan 2026 | Pengumuman | CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 08 Jan 2026 | Pengumuman | CorMedix Therapeutics Announces Leadership and Board Updates |
| 08 Jan 2026 | Pengumuman | CorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business Updates |
| 18 Dec 2025 | Pengumuman | CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |